Respiratory Inhalers Market Size & Growth | Statistics Report 2028

Respiratory Inhalers Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type [Nebulizers, Metered Dose Inhalers (MDI), and Dry Powder Inhalers], Technology (Manually Operated Inhalers and Digitally Operated Inhalers), and Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, and Others)

  • Report Code : TIPRE00003093
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 254
Buy Now

The respiratory inhalers market is expected to grow from US$ 31,144.56 million in 2022 to US$ 43,446.19 million by 2028; it is estimated to record a CAGR of 5.7% from 2022 to 2028.

Respiratory inhalers are used to inhale drugs that are an essential part of treating chronic lung diseases. They are used both to prevent and treat exacerbations of these chronic diseases. They offer the advantage of avoiding systemic drug exposure while ensuring the drugs reach the lungs directly. Numerous products deliver drugs directly into the airways, such as dry powder inhalers, metered dose inhalers (MDIs), nebulizers, and soft mist inhalers. The respiratory inhalers market is expected to grow due to the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Respiratory Inhalers Market: Strategic Insights

respiratory-inhalers-market
Market Size Value inUS$ 31,144.56 million in 2022
Market Size Value byUS$ 43,446.19 million by 2028
Growth rateCAGR of 5.7% from 2022 to 2028
Forecast Period2022-2028
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst
 

Respiratory Inhalers Market Insights

Growing Adoption of Generic Inhalers Drives Growth of Respiratory Inhalers Market

Inhaled medicines involving a wide range of inhalation devices are the mainstay of pharmacological treatment of asthma and COPD. Patients suffering from asthma and COPD often need one or more inhalers daily to keep their airways healthy. Therefore, healthcare professionals are concerned about switching between medications as it can negatively impact disease control through low adherence and misuse of aerosol delivery device types. With increasing pressure on healthcare budgets and the simultaneous expiration of patents on established inhalation treatments, several generic replacement products are being manufactured and supplied across the globe. Several inhalants that are used to treat asthma include generic formulations, such as albuterol, levalbuterol, ipratropium, budesonide, and fluticasone/salmeterol. The generic inhalers are bioequivalent to the branded versions and have the same effect on the body. The number of generic asthma inhalers continues to increase as patents expire. On March 3, 2020, the Food and Drug Administration (FDA) cleared generic asthma inhalers and generic inhaled corticosteroid powder. In April 2020, the FDA approved a generic inhaler, based on albuterol sulfate, to cater to the needs of COVID-19 patients having breathing difficulties. As more generic drugs are entering the market, increased competition is expected, which, in turn, leads to reduced costs of drugs. Cost reductions can also result from the launch of an “approved generic drug.” Thus, the growing adoption of generic inhalers and asthma medications is improving medication adherence, thereby driving the respiratory inhalers market

Product Type-Based Insights

Based on product type, the respiratory inhalers market is segmented into nebulizers, metered dose inhalers, and dry powder inhalers. The dry powder inhalers segment is further bifurcated into multi-dose dry powder inhalers and single-dose dry powder inhalers. The metered dose inhalers (MDI) segment is further divided into pressured metered dose inhalers and connected metered dose inhalers. The nebulizers segment is sub segmented into compressed air nebulizers, mesh air nebulizers, and ultrasonic air nebulizers. In 2022, the dry powder inhalers segment accounted for the largest market share. However, the metered dose inhalers (MDI) segment is anticipated to register the highest CAGR during the forecast period.

Respiratory Inhalers Market, by Product Type– 2022 and 2028

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Technology-Based Insights

Based on technology, the respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held a larger market share in 2022 and is expected to register a higher CAGR during the forecast period.

Disease Indication-Based Insights

Based on disease indication, the global respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.   

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the respiratory inhalers market. A few recent key market developments are listed below:

  • In September 2022, Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP, which is a dry inhaler capsule. ONRIVA TRIO BEXICAP is the preparation of Indacaterol (150 µg), Glycopyrronium (50 µg), and Mometasone (160 µg). It works in 3 ways to control asthma symptoms. Indacaterol and Glycopyrronium help the muscles of lung airways to stay relaxed to prevent bronchoconstriction, while Mometasone helps to decrease inflammation. ONRIVA TRIO BEXICAP is indicated as maintenance therapy in severe persistent asthma.
  • In June 2021, Cipla announced that it had received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the US Food and Drug Administration. Cipla's Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is an AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana.
  • In February 2022, AstraZeneca and Honeywell announced their plans to partner for the development of next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.
  • In January 2023, FDA approved Airsupra [pressurized metered-dose inhaler (pMDI)] in the US for the as-needed treatment or prevention of bronchoconstriction. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.  

Company Profiles   

  • AstraZeneca Plc
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • GSK Plc
  • Koninklijke Philips NV
  • OMRON Corp
  • PARI Respiratory Equipment, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • OPKO Health, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product Type, Technology, and Disease Indication

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is meant by the respiratory inhalers market?

Respiratory inhalers are used to inhale drugs that are an essential part of treating chronic lung diseases. They are used both to prevent and treat exacerbations of these chronic diseases. They offer the advantage of avoiding systemic drug exposure while ensuring the drugs reach the lungs directly. Numerous products deliver drugs directly into the airways, such as dry powder inhalers, metered dose inhalers (MDIs), nebulizers and soft mist inhalers. The respiratory inhaler market is expected to flourish due to the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others.

What are the driving factors for the respiratory inhalers market across the globe?

Key factors driving the market growth are rising cases of respiratory disorders and growing adoption of generic inhalers.

Which segment led the respiratory inhalers market?

The respiratory inhalers market, by product type, is segmented into nebulizers, metered dose inhalers, and dry powder inhalers. The dry powder inhalers segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period (2022–2028).

Which technology segment held the largest revenue (US$ Mn) in the respiratory inhalers market?

Based on technology, the global respiratory inhalers market is divided into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Who are the key players in the respiratory inhalers market?

Companies operating in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH, Cipla Ltd.;GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc..

What is the regional market scenario of the respiratory inhalers market?

Global respiratory inhalers market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is likely to continue its dominance in the respiratory inhalers market during 2022–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period.

The List of Companies - Respiratory Inhalers Market

  1. AstraZeneca Plc
  2. Beximco Pharmaceuticals Ltd.
  3. Boehringer Ingelheim International GmbH
  4. Cipla Ltd.
  5. GSK Plc
  6. Koninklijke Philips NV
  7. OMRON Corp
  8. PARI Respiratory Equipment, Inc.
  9. Teva Pharmaceutical Industries Ltd.
  10. OPKO Health, Inc.  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Respiratory Inhalers Market